Search Weight Loss Topics:

Page 32«..1020..31323334..40..»

Home » Hgh » Page 32

New York Jets running back Le'Veon Bell was once again randomly selected by the NFL to complete an HGH blood test, and he is less than thrilled about it. Back in November, after receiving this same notice five times in 10 weeks he said he would no longer be complying with the tests.

Now we will know for sure if he meant what he said when he informed the NFL via tweet that he will not be doing another test because he was randomly selected once again.

On Friday, he posted the note from the NFL with the caption, "@NFL I bet I don't," suggesting once again that he would not be participating in the mandatory tests.

Refusing to take the test could result in a suspension, and In 2016, a similar situationoccurredwhen he missed multiple tests and was suspended as a result.

His November tweet read:

"[I have] had five 'random' [Human Growth Hormone] blood test in 10 weeks, NFL, I'm not doing another after today. Whatever y'all looking for -- it obviously ain't there. And I'm not about to keep allowing y'all to stick me with those dirty ass needles. Find the players who really do that H.G.H. b.s. and get off me."

Bell told reporters on Friday, "At the end of the day, if we have to cross that bridge when we get there, we'll cross that bridge when we get there. I'm saying right now, the way I feel today, when that tweet went out, that's how I feel."

The note seen in Bell's tweet not only said "immediately" but highlighted it as well. No word on if the 27-year-old reported for the tests.

Bell is certainly no stranger to missing games over something he believes in, so a suspension may not scare him enough to force him to take the tests. Back in 2018, he left a lot of money on the table when he sat out the entire season over contract negotiations with the Pittsburgh Steelers.

Original post:
Le'Veon Bell once again hints he will refuse HGH tests after another randomly selected notice from the NFL - CBS Sports

Joe Rogan was at one point in unbelievable shape. However, when he weighed in after Sober October, that shape became a bit more grotesque.

Rogan is a man of many hats; from commentator, to comedian, and podcast host. Notably he is also something of a fitness advocate, regularly featuring trainers and coaches on his show. This comes as a result of his athletic background, doing Taekwondo and other martial arts. Subsequently, he has been know for being in killer shape.

Unfortunately, it seems at age 52, things are finally starting to catch up to Rogan. He did his annual Sober October activities with a group of his friends. This is a ceremony they do, giving up any drug or alcohol use for the entirety of the month.

Following the conclusion of Sober October, Joe Rogan and company weighed in to see their results. However it was here, that things took a turn for the wild. When Joe took his shirt off for the weigh in, he had a ridiculously protruded midsection. As a result, he looked like he had all of grandmas leftover Christmas banana pudding for a stomach.

Rogan steps on the scale and immediately the talk is about his bloated core. He said he weighed in at 205 pounds, which is ten pounds overweight. Furthermore he attributed this to an uptake in carb consumption. Although looking at his stomach, it seems like a bit worse of a situation than that.

Joe Rogan honestly looks like something you would see in a bodybuilder using too much Human Growth Hormone. This tends to result in a protruding gut, similar to this. All of this is speculation, but if it looks like a duck, and sounds like a duck In any case, it is not uncommon for athletes in that age range to partake in HGH usage.

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.

Read the original here:
Joe Rogan Has an Out Of Control Bubble Gut After Sober October - FitnessVolt.com

A recent market study published by Reports Monitor consists of a detailed evaluation of the key market dynamics. The report provides past as well as present growth parameters of the global Infrared Line Scanners Market. The report features important and unique factors, which are expected to significantly impact the growth of the global Infrared Line Scanners Market throughout the forecast period 2019-2025.

It sheds light on the trends, restraints, and drivers to understand the growth chance followed by the key players in the global Infrared Line Scanners Market.

Get a Sample PDF Report:https://www.reportsmonitor.com/request_sample/806222

The report begin with a scope of the global Infrared Line Scanners Market that includes the key findings and essential statistics of the market. This market research report also consists of the market value of the major segments of the global Infrared Line Scanners Market. Reports Monitor has found a detailed classification and the definition of the global market that helps the readers to better understand the basic information of the Infrared Line Scanners Market. It also highlights the exclusions and inclusions that help the client to understand the scope of the Infrared Line Scanners Market.

Segment by TypePortableFixed

Segment by ApplicationAerospaceGlass IndustryAutomotiveMilitaryOthers

The report consists of key market trends, which are possible to impact the growth of the market over the forecast period 2019- 2025. Evaluation of in-depth industry trends is included in the report, along with their product innovations and key market growth.

Competitive Landscape:The report provides a list of all the key players in the Infrared Line Scanners Market along with a detailed analysis of the strategies, which the companies are adopting. The strategies mainly include new product development, research, and development, and also provides revenue shares, company overview, and recent company developments to remain competitive in the market.

Regional Analysis For Infrared Line Scanners Market:

North America(United States, Canada, and Mexico)Europe(Germany, France, UK, Russia, and Italy)Asia-Pacific(China, Japan, Korea, India, and Southeast Asia)South America (Brazil, Argentina, Colombia, etc.)Middle East and Africa(Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Grab Your Report at an Impressive Discount! Please click [emailprotected]https://www.reportsmonitor.com/check_discount/806222

In this study, the years considered to estimate the market size of the Infrared Line Scanners are as follows:

What our report offers:

For More Details On this Report:https://www.reportsmonitor.com/report/806222/Infrared-Line-Scanners-Market

Contact UsJay MatthewsDirect: +1 513 549-591481 (U.S.)+44 203 318 2846 (U.K.)Email:[emailprotected]

This post was originally published on Market Reports Observer

Read more from the original source:
Global Infrared Line Scanners Market Growth 2019-2025 With Major Players HGH INFRARED SYSTEMES, NDC Technologies, INTERMEC, Optris, Fluke, TIPL,...

First off, its ToTok, not TikTok. One is a messaging app that turned out to be spyware for the United Arab Emirates; the other is that quirky video app that people use to lipsync with their cats to make funny memes. Keep doing that, but definitely remove ToTok from your device if youre one of the millions of people who installed it, because its totally bogus.

The news on ToTok comes from a weekend report by The New York Times, which indicates that ToTokrecently among the most-downloaded apps in the United Statesis actually used by the government of the United Arab Emirates to try to track every conversation, movement, relationship, appointment, sound and image of those who install it on their phones.

While youre uninstalling the offending app, and having a slight panic attack about who and what has this data about your whereabouts and discussions, lets talk prevention. Specifically, is there any way to prevent a scammy app like thisone thats presumably vetted by popularity, as I like to describe itfrom infiltrating your life again?

First off, theres nothing about the apps description that would typically raise a warning flag. Its full of marketing-speak, sure, but its not full of grammar and spelling mistakes, nor does it read as if it was run through Google Translate six times back-to-back. From a screenshot of the apps product page on the App Store, we get:

The app also enjoyed a lot of great reviews and hgh ratingsagain, all appearing to be written by real people. At least, they didnt sound as if the apps developer hired 30 scammers to post random positive junk about the app.

Finally, theres the trust element. I think a lot of people assume that whenever an app makes it onto Apples App Store (for example), it has been thoroughly and properly vetted by Apples internal app review teams. While thats true, to an extent, theres only so much these teams can check. They would have no way of knowing that the servers used by a messaging app are logging and recording everything you saynot really functionality they have the power to test.

The same is true for location tracking. As long as an apps use of location services is directly relevant to the features and services provided by the app, as Apple says, Apple has no control over how this data is stored, kept, or shared by an apps developer. An app can notify and obtain consent before collecting, transmitting, or using location data, but it can also lie. Apple cant check for liars.

Its also unclear whether permissions the app requestedon Android or iOSwould have given away its intent. I suspect that which the app wanted to do probably seemed reasonable, given its a messaging app. It would probably want to access your contacts or SMS messages, as well as your camera, your microphone, et cetera. Normally, an app asking for all those permissions en masse would raise a flag, but not when that app, like others, uses those as part of its core functionality.

The only advice I have, which isnt much advice at all, is to really, really think about the kinds of apps you install on your device. Most app categories have frontrunners that have been around for years, used by millions, and probably analyzed by security experts and journalists alike. Before you install the next great app to replace some critical component of your devicelike a new phone app, a messaging app, or even a camera apptake some time to research it.

Even if you did this, you still wouldnt have found out about ToToks mischief until it was too late, but you also might have not installed the appgiven its newnessuntil more people had more to say about it. You might have paused, wondering why a messaging app youve never heard of and none of your friends are using is now insanely popular. Maybe you would have stuck with Signal or WhatsApp instead of jumping ship to a new app that offers similar functionality. Is the risk worth an extra feature or two, or a more interesting user interface?

Theres no hard and fast rule you can use to determine whether an app is legitimate or not, just a number of data points you have to weigh before installing something new. Sometimes, these clues tilt the balance toward obviousnot a full confirmation, but a strong suggestion that you probably dont need or want the app youre about to install. Other times, like in the case of ToTok, its hard to figure out what you should do. I tend to ask myself, Do I really need it, before I install something new, because I like to not have 1,000 apps on my smartphone. That, and I like to be pretty sure about apps that request a ton of permissions. (Im less worried about apps Ive never heard of that dont need access to, say, my contacts.)

Im hoping you didnt get bit by ToTok, but if you did, its a helpful reminder that even the best-looking apps that live in the top charts on the worlds biggest app playgrounds can still act in bad faith. And, sometimes, theres very little you can do about it. Stay on top of the news for the popular apps you download just in case that new and sweet-looking app is actually a complete and total scam (or worse).

Read the rest here:
Delete the Scammy 'ToTok' App, and Use It As a Lesson in Avoiding Spyware - Lifehacker

Transparency Market Research points out that the competitive landscape in theglobal human growth hormone marketis fairly consolidated. Players continue to focus on developing products with minimal side effects. To expand business to newer markets several vendors are looking at mergers and acquisitions.

Collaborations has become an important part of talent acquisitions for better drug development. For instance OPKO and Pfizer are collaborating to develop and sell human growth hormone hGH-CTP for treating adults and children. Some of the leading players operating in the global human growth hormone market areMerck KGaA, Eli Lilly and Company, Pfizer Inc., Novo Nordisk A/S, and Novartis AG.

According to the research report, the global human growth hormone market is expected to be worth US$ 5,261.5 mn by the end of 2026 in terms of revenue. During the forecast years of 2017 and 2026 the global market for human growth hormone is projected to surge at a CAGR of 6.2%.

Request Sample of Human Growth Hormone Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16283

Out of the many routes of administration, the subcutaneous route of administration is projected to garner the highest revenue of US$1,600 mn by the end of 2026. It continuous to be the most preferred type of chronic growth therapy. From a geographic point of view, North America human growth hormone market is expected to remain in the leading position to strong presence of players.

Rising Incidences of Chronic Conditions amongst Children and Adults Boosts Uptake of Human Growth Market

The growing application of growth hormones in treating many diseases and conditions has created a plethora of opportunities for the global human growth hormone market. The global market for human growth hormone is also being driven by the increasing awareness about the effectiveness of growth hormones in rectifying short statures. Children suffering from congenital conditions have significantly benefited from growth hormones.

Meanwhile, adults with issues pertaining to pituitary gland have also led to a growing demand for human growth hormone therapies. Today, rising incidences of HIV/AIDS, growing research and development of long acting drugs, increasing cases of cancer, improving expenditure on healthcare, and commonly found growth hormone deficiencies have all augmented the global human growth hormone market.

The research report also points out that rising incidences of pituitary tumors, neuropsychiatric-cognitive, skeletal abnormalities, neuromuscular, cardiovascular, and metabolic abnormalities are expected to seek human growth hormone therapies as effective solutions. Majority of these ailments can be alleviated with the help of growth hormones.

The report also states that the human growth hormone therapies are predominantly used for Tuner syndrome as these treatments are designed to treat poor sexual as well as physical developments. Thus, the increasing scope of application of human growth hormones is projected to take the global market to newer heights.

Request for a Discount on Human Growth Hormone Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=16283

Illicit Use of Drugs Likely to Hamper Global Human Growth Hormone Market

On the flip side, the global human growth hormone market is challenged by a few elements. The high cost of these drugs and therapies is the key reason holding the market back from achieving bigger market size. Additionally, illegal usage of growth hormones amongst sportsmen has become the biggest challenge for the global human growth hormone market. The report emphatically states that the adverse side-effects of these drugs is also been a major concern for the overall market.

Go here to read the rest:
Human Growth Hormone Market is Anticipated to Reach Nearly US$ 5261.5 mn by the End of 2026 - Market Reports Observer

A developer wants to build a block of flats with no parking spaces in the middle of the town centre.

Plans for 100 flats next door to Primark in the High Street have been submitted to Watford Borough Council.

The development site is currently home to Bills Restaurant, Supercuts Retail Shop, a casino, Breakout Rooms, offices and car parking spaces at the rear.

The proposal is for a building of fourstoreys, stepping up to nine and 13 storeys to the rear of the building.

No car parking has been proposed.

Developer APG Portfolio Management Limited says the development is within easy reach of the town centre and therefore on-site parking is not considered essential.

No affordable housing is proposed either in its planning application report, the developer referred to the councils Core Strategy Policy HS3 report, which states that only in exceptional circumstances will the council consider a lower level of affordable housing.

APG says it will be left with a shortfall of more than 5.5 million between the proposed benchmark land value of nearly 8 million and the residual land value of 2.3 million.

It added that this is below the necessary level of profit required by lenders in order to fund a scheme and the proposed scheme cannot support the provision of any affordable housing.

The plans for the flatshave been met with some criticism.

Central Watford county councillor Stephen Giles-Medhurst said: We don't need more expensive penthouse appeasements in the town centre.

If they cannot afford to provide much needed social housing then just don't build it.

And Central ward councillor Rabi Martins also hit out at the plans, which he says will overlook the St Marys Church Conservation area if approved.

He said: "A tower in the centre of town which not only affects St Marys Church and its conservation area but also towers oven the new glass dome of the intu centre is totally and utterly unacceptable.

What makes it worse is the refusal of the developer to provide any affordable or social housing claiming they will not make a profit on the development if they do.

Mark Smith, of the Watford Field Residents' Association, added: "The developer's own heritage assessment concludes that there would be harm to the Grade 1 listed St Mary's Church and the St Mary's Conservation Area."

APG says its proposed development preserves and enhances the character and appearance of St Marys Church

A statement from planning agents HGH Consulting added: "This proposed will transform a key part of Watford town centre, which currently attracts high levels of anti-social behaviour, and will contribute towards the continuation of the public realm enhancement programme and investment within the town.

The scheme has evolved through extensive pre-application discussions with Watford Borough Council and their design review panel.

The sustainable and high quality designed development will deliver 100 much needed housing units and new retail/commercial space, on an under-utilised site in a highly accessible town centre location, which will deliver significant improvements to the public realm and pedestrian experience along the High Street."

To view the full planning application, click here. The planning application number is19/01340/FULM

The rest is here:
Flats of up to 13 storeys proposed in Watford town centre - Hillingdon Times

This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll look at Heartland Group Holdings Limited's (NZSE:HGH) P/E ratio and reflect on what it tells us about the company's share price. Based on the last twelve months, Heartland Group Holdings's P/E ratio is 15.60. That means that at current prices, buyers pay NZ$15.60 for every NZ$1 in trailing yearly profits.

Check out our latest analysis for Heartland Group Holdings

The formula for P/E is:

Price to Earnings Ratio = Price per Share Earnings per Share (EPS)

Or for Heartland Group Holdings:

P/E of 15.60 = NZ$1.72 NZ$0.11 (Based on the trailing twelve months to June 2019.)

The higher the P/E ratio, the higher the price tag of a business, relative to its trailing earnings. That isn't necessarily good or bad, but a high P/E implies relatively high expectations of what a company can achieve in the future.

We can get an indication of market expectations by looking at the P/E ratio. You can see in the image below that the average P/E (11.3) for companies in the banks industry is lower than Heartland Group Holdings's P/E.

NZSE:HGH Price Estimation Relative to Market, December 13th 2019

Heartland Group Holdings's P/E tells us that market participants think the company will perform better than its industry peers, going forward. The market is optimistic about the future, but that doesn't guarantee future growth. So investors should always consider the P/E ratio alongside other factors, such as whether company directors have been buying shares.

Companies that shrink earnings per share quickly will rapidly decrease the 'E' in the equation. That means unless the share price falls, the P/E will increase in a few years. Then, a higher P/E might scare off shareholders, pushing the share price down.

It's great to see that Heartland Group Holdings grew EPS by 16% in the last year. And it has bolstered its earnings per share by 4.7% per year over the last five years. So one might expect an above average P/E ratio. Unfortunately, earnings per share are down 1.2% a year, over 3 years.

It's important to note that the P/E ratio considers the market capitalization, not the enterprise value. Thus, the metric does not reflect cash or debt held by the company. In theory, a company can lower its future P/E ratio by using cash or debt to invest in growth.

Such spending might be good or bad, overall, but the key point here is that you need to look at debt to understand the P/E ratio in context.

The extra options and safety that comes with Heartland Group Holdings's NZ$57m net cash position means that it deserves a higher P/E than it would if it had a lot of net debt.

Heartland Group Holdings has a P/E of 15.6. That's below the average in the NZ market, which is 20.0. The net cash position gives plenty of options to the business, and the recent improvement in EPS is good to see. The below average P/E ratio suggests that market participants don't believe the strong growth will continue. Since analysts are predicting growth will continue, one might expect to see a higher P/E so it may be worth looking closer

Story continues

Investors have an opportunity when market expectations about a stock are wrong. If the reality for a company is not as bad as the P/E ratio indicates, then the share price should increase as the market realizes this. So this free visualization of the analyst consensus on future earnings could help you make the right decision about whether to buy, sell, or hold.

Of course, you might find a fantastic investment by looking at a few good candidates. So take a peek at this free list of companies with modest (or no) debt, trading on a P/E below 20.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Originally posted here:
Here's What Heartland Group Holdings Limited's (NZSE:HGH) P/E Is Telling Us - Yahoo Finance

After holding out all of last season, LeVeon Bell signed a four-year contract with the Jets this offseason, worth more than $50 million. Hes experienced a disappointing first season in New York, and now hes making headlines for an off-the-field issue.

Bell believes the NFL is targeting him for drug testing more than other players possibly because of his two drug suspensions in 2015 and 2016. The running back has already been tested five times this year, and he is getting really frustrated about it.

According to the league and players association, NFL players are randomly chosen to be tested for performance-enhancing drugs and recreational drugs, including marijuana. All players are subject to testing throughout the year, with tests often performed during the first two weeks of training camp.

Players in the NFLs drug program are subject to more frequent testing up to six tests per year. Testing involves both an A sample and a B sample, with the B sample serving as a second sample for confirmation if the A sample comes up positive for a banned substance.

Bell tweeted that he has had 5 random HGH blood test[s] in 10 weeks, and hes not doing another after today. Since he is under the six-test limit, if Bell is asked to take another test and refuses, he could face a suspension.

The 27-year-old has already been suspended twice for drug-related violations. After being charged with DUI and marijuana possession in 2014, he was suspended for two games in the 2015 season.

Then, in 2016, he was suspended four games for a missed drug test, which the league considers the same as a failed test. Neither of those suspensions were related to performance-enhancing drugs or HGH, which is what Bell has been tested for five times this year.

Given his history with marijuana, the wide receiver thinks hes being singled out, rather than being subjected to random tests. He said he feels like every time the testers are at the Jets facility to perform HGH testing, he gets picked.

While it seems like Bell is upset with being chosen to be tested so often, he says his real issue is the way hes being tested by having blood drawn. He doesnt like needles, and that is whats bothering him about all of the recent tests.

The wide receiver says if the NFL wants to have him pee in a cup to be tested, he can do that all day, but he doesnt want anything to do with needles.

Peeing in a cup isnt an option for HGH testing. Unlike marijuana, HGH cant be detected in urine and drawing blood is the only reliable test for the substance. This doesnt matter to Bell, who threatens that the league isnt getting no more of my blood. They can use the blood theyve got now.

Between Bells disappointing season and the Jets being in rebuild mode, it seems like the circumstances could lead to a separation between the two after this season. However, the money situation may prevent it from happening.

If the Jets cant trade Bell in the offseason, they are unlikely to cut the veteran running back. It would be a $19 million charge in dead money if the team cuts him.

Bell can opt-out of the last two years of the deal after 2020, but he is unlikely to do so if his lack of production continues next season. At that point, though, the Jets may be more willing to cut him because the cap hit will continue to decrease as time goes on.

See the original post here:
Le'Veon Bell Has Been Drug Tested 5 Times This Year -- and He's Furious - Sportscasting

REPORTING FOR 2019-12-13 | WCX19.ORG: We have done an in-depth analysis of how HGH has been trading over the last 2 weeks and the past day especially. On its latest session, Hartford Financial Services Group, Inc. (The) (NYSE:HGH) opened at 28.19, reaching a high of 28.19 and a low of 28.01 before closing at a price of 28.17. There was a total volume of 42438.

VOLUME INDICATORS FOR HARTFORD FINANCIAL SERVICES GROUP, INC. (THE) (NYSE:HGH): We saw an accumulation-distribution index of 78.644, an on-balance volume of 28.19, chaikin money flow of 0.50018 and a force index of 0.0168. There was an ease of movement rating of 0.00045, a volume-price trend of -0.64158 and a negative volume index of 1000.0.

VOLATILITY INDICATORS FOR HARTFORD FINANCIAL SERVICES GROUP, INC. (THE) (NYSE:HGH): We noted an average true range of 0.11702, bolinger bands of 28.04828, an upper bollinger band of 27.99172, lower bollinger band of 28.01, a bollinger high band indicator of 1.0, bollinger low band indicator of 1.0, a central keltner channel of 28.13, high band keltner channel of 28.13, low band keltner channel of 28.13, a high band keltner channel indicator of 1.0 and a low band keltner channel indicator of 1.0. There was a donchian channel high band of 28.01, a donchian channel low band of 28.01, a donchian channel high band indicator of 1.0, and a donchian channel low band indicator of 1.0.

TREND INDICATORS FOR HARTFORD FINANCIAL SERVICES GROUP, INC. (THE) (NYSE:HGH): We calculated a Moving Average Convergence Divergence (MACD) of 0.00045, a MACD signal of 0.00025, a MACD difference of 0.0002, a fast Exponential Moving Average (EMA) indicator of 28.01, a slow Exponential Moving Average (EMA) indicator of 28.01, an Average Directional Movement Index (ADX) of unknown, an ADX positive of 20.0, an ADX negative of 20.0, a positive Vortex Indicator (VI) of 1.0, a negative VI of 1.0, a trend vortex difference of 0.08814, a trix of -1.74951, a Mass Index (MI) of 1.8, a Commodity Channel Index (CCI) of -66.66667, a Detrended Price Oscillator (DPO) of 0.65305, a KST Oscillator (KST) of -22.78365 and a KST Oscillator (KST Signal) of -22.78365 (leaving a KST difference of 0.17444). We also found an Ichimoku rating of 28.19, an Ichimoku B rating of 28.19, a Ichimoku visual trend A of 28.75705, an Ichimoku visual trend B of 28.59641, an Aroon Indicator (AI) up of 4.0 and an AI indicator down of 4.0. That left a difference of 4.0.

MOMENTUM INDICATORS FOR HARTFORD FINANCIAL SERVICES GROUP, INC. (THE) (NYSE:HGH): We found a Relative Strength Index (RSI) of 50.0, a Money Flow Index (MFI) of 49.97623, a True Strength Index (TSI) of -100.0, an ultimate oscillator of -38.05103, a stochastic oscillator of 50.0, a stochastic oscillator signal of 50.0, a Williams %R rating of -50.0 and an awesome oscillator of -0.0333.

RETURNS FOR HARTFORD FINANCIAL SERVICES GROUP, INC. (THE) (NYSE:HGH): There was a daily return of -2.27837, a daily log return of 0.07138 and a cumulative return of 0.0714.

What the heck does all of this mean? If you are new to technical analysis, the above may be gibberish to you, and thats OK (though we do advise learning these things). The bottom line is that AS OF 2019-12-13 (if you are reading this later, the analysis will be out of date), here is what our deep analysis of technical indicators are telling us for Hartford Financial Services Group, Inc. (The) (NYSE:HGH)

DISCLAIMER: We are not registered investment advisers and the above analysis should be taken at face value only. We strongly advise against buying or selling Hartford Financial Services Group, Inc. (The) (NYSE:HGH) based solely on our analysis above, and are not responsible for any losses that you may incur if you choose make any investment decisions based on the above.

Link:
Hartford Financial Services Group, Inc. (The) (NYSE:HGH): Caution Is Advised (2019-12-13) - WCX19

The following are the top rated Healthcare stocks according to Validea's Price/Sales Investor model based on the published strategy of Kenneth Fisher. This value strategy rewards stocks with low P/S ratios, long-term profit growth, strong free cash flow and consistent profit margins.

UNITED THERAPEUTICS CORPORATION (UTHR) is a mid-cap value stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Kenneth Fisher is 68% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

OPKO HEALTH INC. (OPK) is a small-cap value stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Kenneth Fisher is 60% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women's Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

AMAG PHARMACEUTICALS, INC. (AMAG) is a small-cap value stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Kenneth Fisher is 50% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

ENDO INTERNATIONAL PLC (ENDP) is a small-cap value stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Kenneth Fisher is 50% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: Endo International plc is a generics and specialty branded pharmaceutical company. The Company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals and International Pharmaceuticals. It has a portfolio of branded pharmaceuticals offered by its U.S. Branded Pharmaceuticals segment that includes brand names, such as Lidoderm, OPANA ER, Voltaren Gel, Percocet, Fortesta Gel, Testim, TESTOPEL, Aveed, Supprelin LA and XIAFLEX. Its non-branded U.S. Generic Pharmaceuticals portfolio consists of products, such as tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics and patches. The Company's generics portfolio has a range of dosage forms and delivery systems. The International Pharmaceuticals segment includes various specialty pharmaceutical products for the Canadian, Latin American and world markets.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

ENANTA PHARMACEUTICALS INC (ENTA) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Kenneth Fisher is 50% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

Since its inception, Validea's strategy based on Kenneth Fisher has returned 410.16% vs. 218.76% for the S&P 500. For more details on this strategy, click here

About Kenneth Fisher: The son of Philip Fisher, who is considered the "Father of Growth Investing", Kenneth Fisher is a money manager, bestselling author, and longtime Forbes columnist. The younger Fisher wowed Wall Street in the mid-1980s when his book Super Stocks first popularized the idea of using the price/sales ratio (PSR) as a means of identifying attractive stocks. According to his alma mater, Humboldt State University, Fisher is also one of the world's foremost experts on 19th century logging. Appropriately, Fisher's firm, Fisher Investments, is located in a lush forest preserve in Woodside, California, where the contrarian-minded Fisher says he and his employees can get away from Wall Street groupthink.

About Validea: Validea is an investment research service that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Read the original post:
Validea's Top Five Healthcare Stocks Based On Kenneth Fisher - 12/15/2019 - Nasdaq

Page 32«..1020..31323334..40..»

Home » Hgh » Page 32